Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Studies Previous | All Articles This Week | Next
This article originally posted 29 May, 2009 and appeared in  Issue 470

Tolerx Phase 3 Study

DEFEND is a Phase 3 clinical study of otelixizumab in YOUNG ADULTS with newly diagnosed T1DM.

Otelixizumab is an investigational agent, not yet approved by the FDA for marketing. DEFEND will determine if otelixizumab can help preserve the ability to make endogenous insulin and stop the destruction of the body's cells that make insulin (beta cells). You can find out more at: www.defendagainstdiabetes.com
Advertisement
Advertisement

 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2009 and appeared in  Issue 470

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control

Cardiovascular CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews GLP-1 Agonist Sheri R. Colberg, PhD

Announcement:
 

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes




Search Articles On Diabetes In Control